Prolor Biotech Inc. reported positive results in a study of its new version of the hemophilia drug Factor VIIa-CTP in a pre-clinical trial on mice. The study showed that mice which received the longer-acting version of the drug showed a higher survival and recovery rate over a longer period of time, compared to those that received the commercially available version of the drug. According to the company, mice that received Factor VIIa-CTP also showed a longer-lasting generation of the pro-clotting enzyme ‘thrombin.’ View and share
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Israel Foodtech Firms Meet UK Retailers, Investors In London
April 17, 2024
Facebook comments